FARAPULSE is changing how arrhythmias are treated with a generational breakthrough. Our technology – pulsed field ablation or “PFA” – represents a fundamentally different and improved therapy.
FARAPULSE is the pioneer of a new era in cardiac ablation. Comprised of passionate and accomplished professionals, our shared experience drives a conviction that a safer, more durable and more efficient modality is due. Tested over many years, FARAPULSE PFA promises a leap forward and is now available for use in select patients1 and CE Mark geographies.
Since 2013 FARAPULSE has led the development of cardiac PFA, championing this innovative energy source’s potential to safely and effectively ablate all arrhythmias, including atrial fibrillation (AF). Having developed the first cardiac PFA system ever put into human use, FARAPULSE has developed a comprehensive library of advanced preclinical and clinical data. In European clinical studies, FARAPULSE PFA was shown to produce none of the severe complications associated with traditional AF ablation – PV stenosis and esophageal and phrenic nerve injury – while achieving 85% freedom from AF at one year.2
1 - The FARAWAVE Pulsed Field Ablation (PFA) Catheter is indicated for cardiac tissue ablation for the treatment of paroxysmal atrial fibrillation.
2 - Reddy VY, Dukkipati SR, Neuzil P, et al. Pulsed Field Ablation of Paroxysmal Atrial Fibrillation: 1-Year Outcomes of IMPULSE, PEFCAT, and PEFCAT II. JACC Clin Electrophysiol. 2021;7(5):614-627. doi:10.1016/j.jacep.2021.02.014